The global genomics market size was estimated at USD 28,900 million in 2022 and is projected to reach around USD 1,27,160 million by 2032, growing at a CAGR of 16.1% from 2023 to 2032.
The global genomics market size was estimated at USD 28,900 million in 2022 and is projected to reach around USD 1,27,160 million by 2032, growing at a CAGR of 16.1% from 2023 to 2032.
The global genomics market is projected to surpass around USD 84,470 million by 2029, as a result of rising technology advancements and increasing demand for personalized medicine.
Download a short version of this report @ https://www.towardshealthcare.com/personalized-scope/5065
Precision Medicine and Genomic Data Integration: Driving Market Growth
Precision medicine adoption, coupled with the integration of genomic data for personalized care, is propelling the growth of the genomics market. Genomics, the study of an individual’s genetic material, plays a pivotal role in comprehending the genetic foundations of diseases, developing targeted therapies, and facilitating precision medicine.
Diverse Applications Driving Market Expansion
The genomics market is witnessing significant expansion due to
- the increasing prevalence of genetic disorders
- rising adoption of genomic medicine in clinical practice
- expanding applications in areas such as oncology, rare diseases, pharmacogenomics, and agriculture.
Technological Advancements and Market Transformation
The genomics market is undergoing rapid growth and transformation, spurred by technological advancements, decreasing sequencing costs, and an escalating demand for personalized medicine. Various technologies, including next-generation sequencing (NGS), polymerase chain reaction (PCR), microarray analysis, and gene editing tools such as CRISPR-Cas9, are contributing to the market’s evolution. These technologies empower researchers and clinicians to analyze and interpret genetic information, offering crucial insights into disease mechanisms, drug discovery, and patient care.
Customize this study as per your requirement @ https://www.towardshealthcare.com/customization/5065
Role of Genetic Diseases in Market Growth
The growing prevalence of genetic diseases is a key driver for the genomics market. Genetic disorders, including cancer, cardiovascular disorders, rare genetic disorders, and inherited diseases, significantly impact global health. With approximately 10,000 types of single-gene diseases, affecting around 10 out of every 1000 people globally, the demand for genomic solutions and services is on the rise.
Genomics in Diagnosis and Treatment of Genetic Diseases
Genomics plays a pivotal role in diagnosing, predicting, and treating genetic diseases. The increasing understanding of the genetic basis of these diseases, such as Down syndrome, emphasizes the importance of genomics. In the U.S., around 6,000 babies are born with Down syndrome annually. Genomics aids in identifying genetic variants associated with diseases, enabling personalized medicine approaches.
Affordability and Accessibility Driving Adoption
The decreasing costs of genomic sequencing and the availability of large-scale genomic databases have made genetic testing and genomic profiling more accessible and affordable. This accessibility benefits both healthcare providers and patients, underscoring the importance of genomics in population health management and public health initiatives.
You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com
The Role of PCR Technology in the Genomics Market
The PCR technology holds the largest market share and is projected to be the fastest-growing technology over the forecast period.
The genomics market is driven by various technologies, and one prominent technology in this field is Polymerase Chain Reaction (PCR). PCR is a widely used technique that allows for the amplification and analysis of specific DNA sequences. It plays a crucial role in genomics research and applications.
In the genomics market, PCR technology has witnessed significant advancements, leading to the development of various PCR-based techniques. These include real-time PCR (qPCR), digital PCR (dPCR), reverse transcription PCR (RT-PCR), and multiplex PCR, among others. Each technique has its advantages and applications, catering to different research and diagnostic needs. The adoption of PCR technology in the genomics market is driven by factors such as its accuracy, versatility, and cost-effectiveness. PCR-based assays are extensively used in academic research, pharmaceutical and biotechnology companies, clinical laboratories, and forensic laboratories.
Browse More Insights of Towards Healthcare:
- The global AI in genomics market size is estimated to grow from USD 397.64 million in 2022 to reach an estimated USD 7,365.59 million by 2032 at CAGR of 23.6% between 2023 and 2032.
- The global lung disease therapeutics market size reached USD 81.2 billion in 2022 and is anticipated to hit around USD 146.1 billion by 2032, expanding at a CAGR of 6.1% from 2023 to 2032.
- The global brain computer interface market size is estimated to grow from USD 2,130 million in 2022 to reach an estimated USD 9,445.1 million by 2032 at 16.7% CAGR from 2023 to 2032.
- Overview of newborn imaging system market size is estimated to grow from USD 277.64 million in 2022 to reach an estimated USD 441.42 million by 2032 at 4.6% CAGR from 2023 to 2032.
- The global liquid biopsy market is estimated to grow from USD 4,722.73 million in 2022 to reach an estimated USD 18,280.13 million by 2032 at 14.5% CAGR between 2023 and 2032.
Geographical Landscape of the Genomics Market
North America, particularly the United States, dominates the genomics market and holds the largest market share. The region’s leadership can be attributed to factors such as strong research infrastructure, significant investments in genomics research, and the presence of key market players. The United States has a robust genomics ecosystem, including academic research institutions, pharmaceutical companies, and genomics service providers.
Following the passage of the Fiscal Year 2022 federal budget by the U.S. Congress on March 11, the National Institutes of Health (NIH) received approximately $45 billion, representing a $2.03 billion increase in funding. Specifically, the National Human Genome Research Institute (NHGRI) has been allocated a budget of $639 million, reflecting a 3.8% increase compared to the previous year. This positive development allowed NHGRI to proceed with its planned research activities for 2022, ensuring continued progress in the field of genomics.
The country has been at the forefront of large-scale genomics initiatives, such as the Precision Medicine Initiative and the All of Us Research Program, driving the adoption of genomics in healthcare.
In addition to the United States, Europe is a prominent market for genomics, with countries like the United Kingdom, Germany, and France leading in terms of research and clinical implementation. Europe has a strong regulatory framework for genetic testing and personalized medicine, supporting the integration of genomics into healthcare systems.
Asia-Pacific is a rapidly growing market for genomics, driven by increasing investments in genomics research, the rising prevalence of genetic diseases, and the expanding demand for personalized medicine. Countries like China, Japan, and India are making significant strides in genomics research, fueling market growth in the region. In the upcoming years, Asia-Pacific is projected to be the fastest-growing region in the genomics market. The region’s large population, growing healthcare infrastructure, and government initiatives to promote genomics research and precision medicine contribute to its growth potential. The increasing focus on precision healthcare and personalized medicine in emerging economies presents lucrative opportunities for market players in the region.
Some major market players involved in the genomics market are Thermo Fisher Scientific, Inc., Illumina, Inc., Oxford Nanopore Technologies, QIAGEN N.V., BGI, Eurofins Scientific, GE Healthcare, Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., and Hoffmann-La Roche Ltd.
Recent Developments by Key Market Players
- In February 2023, Roche announced an expansion of its collaboration with Janssen Biotech Inc. The aim of this collaboration is to develop companion diagnostics that can be used alongside targeted therapies.
- In September 2022, Thermo Fisher Scientific collaborated with the Taiwan Precision Medicine Initiative (TPMI) to advance a large-scale genomics study and assist in genotyping one million individuals in Taiwan.
- In April 2022, Thermo Fisher Scientific introduced the Ion Torrent Genexus Dx Integrated Sequencer with the CE-IVD grading, a rapid, platform for next-generation sequencing (NGS) which is automated and enabling same-day results.
- In December 2021, Roche announced the launch of the AVENIO Edge System, an integral part of the company’s strategy to advance sequencing technologies. The AVENIO Edge System is a fully-automated, integrated sequencing solution that is built on top-notch foundational capabilities.
Market Segments:
By Product and Services
- Consumables
- Systems and software
- Services Equipment
By Technology
- PCR (polymerase chain reaction)
- Sequencing
- Microarray
- Nucleic acid extraction and purification
- Other technologies (branched DNA analysis, single-cell genomics analysis, and flow cytometry)
By Application
- Drug discovery and development
- Diagnostics
- Precision medicine
- Agriculture and animal research
- Other applications
By End-Users
- Hospitals & clinics
- Research centers and academic & government institutes
- Pharmaceutical & biotechnology companies
- Other end users
By Regional Outlook
- North America
- US.
- Canada
- Europe
- UK.
- Germany
- France
- Asia Pacific
- China
- India
- Japan
- Southeast Asia
- Middle East and Africa
- GCC
- North Africa
- South Africa
- Rest of MEA
You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com
Explore the comprehensive statistics and insights on healthcare industry data and its associated segmentation: Get a Subscription
About Us
Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations. We are a global strategy consulting firm that assists business leaders in gaining a competitive edge and accelerating growth. We are a provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations.
Web: https://www.towardshealthcare.com
Browse our Brand-New Journal@ https://www.towardspackaging.com
Browse our Consulting Website@ https://www.precedenceresearch.com
For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare